Press Releases

  • 16 Feb 2017
    - Press Release

    EBE and EFPIA support ARM Initiative on Hospital Exemptions and Call for Increased Transparency on All Advanced Cell, Gene and Tissue Therapies

    Brussels, 16 February 2017 - The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) today express their support for key aspects of the “Position on Hospital Exemption” for Advanced Therapy Medicinal Products (ATMPs), developed by the Alliance for Regenerative Medicines (ARM). ARM, EBE and EFPIA call for greater transparency on all ATMPs available to patients, whether through EU authorisation or national exemptions issued in accordance with Article 28 (2) of the Advanced Therapy Medicinal Product Regulation[1].

    Read more |
  • 19 Oct 2016
    - Press Release

    EFPIA and EBE Welcome NOR-SWITCH Results as a Valuable Step Forward

    EFPIA and EBE welcome the results of the NOR-SWITCH study on biosimilar switching* and acknowledge its preliminary results as a step in the right direction of robust data generation that continues to enhance physician and patient confidence in using biosimilars.

    EFPIA and EBE also welcome the effort of the Norwegian authorities and investigators to initiate and carry out the NOR-SWITCH study.

    Read more |
  • 19 Sep 2016
    - Press Release

    The European biotech ecosystem: EBE position paper recommends how to make funding go further

    Brussels, 19 September 2016

    The European Biopharmaceutical Enterprises (EBE) today published a White Paper that scrutinises funding available for innovative biopharmaceutical entrepreneurs in Europe and explores why fewer successful businesses are built in Europe – despite our exceptional science – than in other world regions.

    Read more | Download Document (547.59 kB)
  • 18 Jun 2016
    - Press Release

    EBE Webinar: "Maintaining Europe's Lead In Regenerative Medicine - New Approaches and Programmes"

    Webinar - 1 July 2016 - 11.45-12.30 CET

    While the EU has had a global lead in ATMP technologies and regulation policy, other countries are moving aggressively into the space.

    The Japanese "Sakigake" accelerated pathway for regenerative medicines, as well as initiatives such as the UK's EAMs and EMA's PRIME are such examples.
    What are the National Governments and European Commission doing specifically to ensure that ATMP technologies are continued to be developed and commercialised in Europe?
    Read more |